Artivion's NEXUS Device Shows Promising Results in Aortic Disease Treatment Advances
- Artivion's NEXUS device shows a 63% reduction in Major Adverse Events for chronic aortic dissection patients.
- The NEXUS device's technical failure rate is low at 1.9%, surpassing the goal of 30%.
- Artivion's trial results position the company as a leader in innovative aortic disease treatment solutions.
Artivion Advances Aortic Disease Treatment with Promising Clinical Data
Artivion, Inc., a leader in cardiac and vascular surgery specializing in aortic disease, showcases significant advancements in the treatment of chronic aortic dissection through its Endospan NEXUS TRIOMPHE IDE trial. Recently presented at the 105th American Association for Thoracic Surgery Annual Meeting in Seattle, these new clinical findings highlight the efficacy of the NEXUS device in a high-risk patient cohort. The trial, which included 54 patients identified as unsuitable for traditional open surgical repair, reveals a remarkable 63% reduction in the Major Adverse Event (MAE) rate, achieving only 13% compared to a performance benchmark of 35%. This outcome, statistically significant with a p-value of less than 0.001, underscores the potential of the NEXUS device to provide safer, minimally invasive treatment options for patients facing dire surgical risks.
Further emphasizing the success of the trial, the technical failure rate of the NEXUS device stands impressively low at 1.9%, significantly better than the anticipated goal of 30% (p < 0.001). The MAEs noted in the study include serious complications such as mortality, disabling stroke, renal failure, and aortic rupture, all of which pose substantial risks in surgical interventions for chronic aortic dissection. Dr. Bradley Leshnower, a professor of surgery at Emory University and key presenter of the trial findings, articulates the NEXUS device as a transformative tool in addressing these high-stakes medical challenges. The promising results not only validate the device’s effectiveness but also expand treatment avenues for patients who previously had limited options.
Artivion's leadership, represented by Chairman, President, and CEO Pat Mackin, expresses optimism about the trial's 30-day outcomes and the anticipation of one-year results. The company views these findings as pivotal in establishing the NEXUS device as a viable therapeutic alternative for patients suffering from aortic arch disease. The NEXUS TRIOMPHE trial represents a crucial step in enhancing patient care and outcomes for those with severe surgical risks, aligning with Artivion’s mission to innovate within the cardiac and vascular surgery space.
In related developments, the presentation of the NEXUS TRIOMPHE trial data at a prestigious forum like the American Association for Thoracic Surgery Annual Meeting positions Artivion as a frontrunner in the field. The positive reception of these results may bolster the company’s reputation and pave the way for further research and clinical applications of the NEXUS device. As the medical community continues to explore minimally invasive solutions for complex aortic conditions, Artivion remains at the forefront of this transformative movement.
Related Cashu News

Merit Medical Systems Launches Employee Stock Ownership Plan to Boost Engagement and Stability
Merit Medical Systems (Ticker: MMSI) recently takes a significant step in enhancing its employee engagement and ownership structure with the launch of a new Employee Stock Ownership Plan (ESOP). The c…

Brookdale Senior Living launches second season of educational podcast "The Grey Take.
Brookdale Senior Living (Ticker: BKD) launches the second season of its popular podcast, "The Grey Take," which serves as a valuable resource for families exploring senior living options. The podcast…

Molina Healthcare Gains Momentum with Increased Risk Adjustment Payments and Positive Revenue Outlook
Molina Healthcare (Ticker: MOH) is making significant strides in its revenue outlook due to recently released risk adjustment figures from the Centers for Medicare & Medicaid Services (CMS). These upd…

Align Technology Faces Antitrust Investigation by European Commission Over Competitive Practices
Align Technology Inc. (Ticker: ALGN) faces a formal antitrust investigation from the European Commission, marking a significant development in the medical devices sector. This inquiry arises from a co…

